Xilio Therapeutics (XLO) Net Equity Issued and Repurchased (2021 - 2026)

Xilio Therapeutics (XLO) posted Net Equity Issued and Repurchased of $2.0 million for Q1 2025, up 201600.0% sequentially from $1000.0 in Q4 2024.

Xilio Therapeutics (XLO) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends

Xilio Therapeutics has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $2.0 million in Q1 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $2.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (up 107.07% YoY) and the FY2025 annual result came in at $2.0 million, down 70.45% from the prior year.
Net Equity Issued and Repurchased improved to $2.0 million in Q1 2025 per XLO's latest filing, from $1000.0 in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $144.9 million in Q1 2021 and troughed at -$28.5 million in Q4 2021.
A 3-year average of $29.6 million and a median of $1.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Xilio Therapeutics	178.33 Mn	42.29 Mn	-	-

Download Data